Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Nelleke Snelder

Showing results (1-10 of 27) with videos related to

Pageof 3
Sort By:
CPT: Pharmacometrics & Systems Pharmacology|July 16, 2024
Time-varying covariates, overadjustment bias and mediation in pharmacokinetic/pharmacodynamic modelingSebastiaan Camiel Goulooze, Nelleke Snelder
The Journal of Family Planning and Reproductive Health Care|March 16, 2013
Characterisation of the pharmacokinetics of ethinylestradiol and drospirenone in extended-cycle regimens: population pharmacokinetic analysis from a randomised Phase III studyStefanie Reif, Nelleke Snelder, Hartmut Blode
Journal of Pharmacokinetics and Pharmacodynamics|February 4, 2021
A population K-PD model analysis of long-term testosterone inhibition in prostate cancer patients undergoing intermittent androgen deprivation therapyJoost DeJongh, Maurice Ahsman, Nelleke Snelder
CPT: Pharmacometrics & Systems Pharmacology|January 19, 2026
Tutorial on Causal Mediation Analysis for PharmacometriciansSebastiaan Camiel Goulooze, Eleonora Marostica, Nelleke Snelder
CPT: Pharmacometrics & Systems Pharmacology|June 13, 2024
Quantification of the effect of GLP-1R agonists on body weight using in vitro efficacy information: An extension of the Hall body composition modelRolien Bosch, Eric J G Sijbrands, Nelleke Snelder
CPT: Pharmacometrics & Systems Pharmacology|March 12, 2026
Impact of Event-Related Treatment Modifications in Exposure-Response Analyses of Repeated Time-to-Event DataSebastiaan Camiel Goulooze, Nelleke Snelder, Thomas Eissing, et al.
Drug Metabolism and Disposition: the Biological Fate of Chemicals|June 27, 2014
Translational pharmacokinetic modeling of fingolimod (FTY720) as a paradigm compound subject to sphingosine kinase-mediated phosphorylationNelleke Snelder, Bart A Ploeger, Olivier Luttringer, et al.
Journal of Pharmacokinetics and Pharmacodynamics|September 15, 2020
Population pharmacokinetics and pharmacodynamics of a novel vascular adhesion protein-1 inhibitor using a multiple-target mediated drug disposition modelNelleke Snelder, Sven Hoefman, Alberto Garcia-Hernandez, et al.
CPT: Pharmacometrics & Systems Pharmacology|July 16, 2025
From In Vitro Efficacy to Long-Term HbA1c Response for GLP-1R/GlucagonR Agonism Using the 4GI-HbA1c Systems ModelRolien Bosch, Marcella Petrone, Rosalin Arends, et al.
Pharmaceutics|April 28, 2023
Evaluation of a Cardiovascular Systems Model for Design and Analysis of Hemodynamic Safety StudiesYu Fu, Nelleke Snelder, Tingjie Guo, et al.
Pageof 3

Showing results (1-10 of 27) with videos related to

Sort By:
Pageof 3
CPT: Pharmacometrics & Systems Pharmacology|July 16, 2024
Time-varying covariates, overadjustment bias and mediation in pharmacokinetic/pharmacodynamic modelingSebastiaan Camiel Goulooze, Nelleke Snelder
The Journal of Family Planning and Reproductive Health Care|March 16, 2013
Characterisation of the pharmacokinetics of ethinylestradiol and drospirenone in extended-cycle regimens: population pharmacokinetic analysis from a randomised Phase III studyStefanie Reif, Nelleke Snelder, Hartmut Blode
Journal of Pharmacokinetics and Pharmacodynamics|February 4, 2021
A population K-PD model analysis of long-term testosterone inhibition in prostate cancer patients undergoing intermittent androgen deprivation therapyJoost DeJongh, Maurice Ahsman, Nelleke Snelder
CPT: Pharmacometrics & Systems Pharmacology|January 19, 2026
Tutorial on Causal Mediation Analysis for PharmacometriciansSebastiaan Camiel Goulooze, Eleonora Marostica, Nelleke Snelder
CPT: Pharmacometrics & Systems Pharmacology|June 13, 2024
Quantification of the effect of GLP-1R agonists on body weight using in vitro efficacy information: An extension of the Hall body composition modelRolien Bosch, Eric J G Sijbrands, Nelleke Snelder
CPT: Pharmacometrics & Systems Pharmacology|March 12, 2026
Impact of Event-Related Treatment Modifications in Exposure-Response Analyses of Repeated Time-to-Event DataSebastiaan Camiel Goulooze, Nelleke Snelder, Thomas Eissing, et al.
Drug Metabolism and Disposition: the Biological Fate of Chemicals|June 27, 2014
Translational pharmacokinetic modeling of fingolimod (FTY720) as a paradigm compound subject to sphingosine kinase-mediated phosphorylationNelleke Snelder, Bart A Ploeger, Olivier Luttringer, et al.
Journal of Pharmacokinetics and Pharmacodynamics|September 15, 2020
Population pharmacokinetics and pharmacodynamics of a novel vascular adhesion protein-1 inhibitor using a multiple-target mediated drug disposition modelNelleke Snelder, Sven Hoefman, Alberto Garcia-Hernandez, et al.
CPT: Pharmacometrics & Systems Pharmacology|July 16, 2025
From In Vitro Efficacy to Long-Term HbA1c Response for GLP-1R/GlucagonR Agonism Using the 4GI-HbA1c Systems ModelRolien Bosch, Marcella Petrone, Rosalin Arends, et al.
Pharmaceutics|April 28, 2023
Evaluation of a Cardiovascular Systems Model for Design and Analysis of Hemodynamic Safety StudiesYu Fu, Nelleke Snelder, Tingjie Guo, et al.
Pageof 3